Perez Mauricio, Barrionuevo Vanessa, Arias Cristina, Baehring Joachim M
Neuro-Oncology, Yale University, New Haven, USA.
General Practice, Universidad de Guayaquil, Guayaquil, ECU.
Cureus. 2024 Jun 2;16(6):e61540. doi: 10.7759/cureus.61540. eCollection 2024 Jun.
The standard chemotherapy for treating oligodendrogliomas consists of a combination of procarbazine, lomustine, and vincristine (PCV). The combination of hypomethylating agents like azacitidine and BCL2 inhibitors like venetoclax has not been formally studied in the treatment of glial tumors. The combination of these two drugs is commonly used to treat acute myeloid leukemia (AML), with IDH-mutant disease being a particularly sensitive subtype. The use of azacitidine for the treatment of IDH-mutant gliomas has been reported in the literature, with mixed results that might suggest at least some benefits in a subtype of patients. It is also reported in the literature that the BCL2 gene is associated with treatment resistance and tumor recurrence in gliomas. Here, we present a patient with an oligodendroglioma who was treated with a conventional chemotherapy regimen for AML and, at the same time, had a favorable radiographic response to his brain tumor.
治疗少突胶质细胞瘤的标准化疗方案是丙卡巴肼、洛莫司汀和长春新碱（PCV）联合使用。像阿扎胞苷这样的低甲基化剂与像维奈克拉这样的BCL2抑制剂联合使用，在胶质细胞瘤治疗中尚未得到正式研究。这两种药物联合常用于治疗急性髓系白血病（AML），其中异柠檬酸脱氢酶（IDH）突变型疾病是特别敏感的亚型。文献报道了使用阿扎胞苷治疗IDH突变型胶质瘤，结果不一，这可能表明至少对部分患者亚型有一定益处。文献还报道，BCL2基因与胶质瘤的治疗耐药性和肿瘤复发有关。在此，我们介绍一名少突胶质细胞瘤患者，其接受了针对AML的传统化疗方案治疗，同时其脑肿瘤在影像学上有良好反应。
